首页> 外文期刊>Environmental toxicology and pharmacology >The effects of different treatments on prolidase and antioxidant enzyme activities in patients with bronchial asthma
【24h】

The effects of different treatments on prolidase and antioxidant enzyme activities in patients with bronchial asthma

机译:不同治疗方法对支气管哮喘患者血浆蛋白酶和抗氧化酶活性的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The effects of two different treatment combinations of bronchial asthma on antioxidant defense systems and serum prolidase activity were investigated. The groups were organized as follows: the first group (control) consisted of healthy subjects. The second group (treatment 1) consisted of patients with bronchial asthma inhaling budesonide (2 x 400 mcg/d, as puff) + formaterol (2 x 9 mcg/d, as puff). In the third group (treatment 2) patients with bronchial asthma were treated with montelukast (1 x 10 mg/d, as pill) + budesonide (2 x 400 mcg/d, as puff) + formaterol (2 x 9 mcg/d, as puff). The medical therapy of the patients in treatment 1 and treatment 2 lasted 12 weeks. Before and after treatment in all three groups blood samples were taken and the level of thiobarbituric acid-reactive substances (TBARS) and the activities of prolidase, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GSSG-Rd) and catalase (CAT) were measured. Prolidase activity was found to be significantly higher in patients compared to control (p < 0.05). Treatment 2 was successfully reduced the prolidase activity (p < 0.05). Before treatments, SOD activity was significantly decreased whereas TBARS level and other antioxidant enzymes were increased in both treatment groups comparing with control (p < 0.05). Both of different treatments given in treatment 1 and treatment 2 groups caused significant increase in SOD whereas decrease in TBARS, CAT, GSSG-Rd, GSH-Px (p < 0.05). When compared the treatment groups after treatments, SOD activity was significantly higher in treatment 2 group than treatment 1 group (p < 0.05). No significant difference was seen in other parameters. The balance between oxidant-antioxidant system is impaired in patients with asthma.
机译:研究了两种不同的支气管哮喘治疗组合对抗氧化防御系统和血清脯氨酸酶活性的影响。各组的组织如下:第一组(对照组)由健康受试者组成。第二组(治疗1)由支气管哮喘患者吸入布地奈德(2 x 400 mcg / d,以粉扑)+甲硝酚(2 x 9 mcg / d,以粉扑)组成。在第三组(治疗2)中,支气管哮喘患者接受了孟鲁司特(1 x 10毫克/天,作为药丸)+布地奈德(2 x 400 mcg /天,作为粉扑)+甲福洛尔(2 x 9 mcg / d,如粉扑)。治疗1和治疗2的患者的药物治疗持续了12周。在治疗前和治疗后三组均采集血样,硫代巴比妥酸反应性物质(TBARS)的水平以及脯氨酸酶,超氧化物歧化酶(SOD),谷胱甘肽过氧化物酶(GSH-Px),谷胱甘肽还原酶(GSSG-Rd)的活性)和过氧化氢酶(CAT)。发现患者中的脯氨酸蛋白酶活性明显高于对照组(p <0.05)。处理2成功降低了蛋白酶的活性(p <0.05)。在治疗前,与对照组相比,两个治疗组中的SOD活性均显着降低,而TBARS水平和其他抗氧化酶均升高(p <0.05)。在治疗1和治疗2组中给予的不同治疗均导致SOD显着增加,而TBARS,CAT,GSSG-Rd,GSH-Px降低(p <0.05)。与治疗后的治疗组比较,治疗2组的SOD活性明显高于治疗1组(p <0.05)。其他参数无明显差异。哮喘患者的抗氧化剂-抗氧化剂系统之间的平衡受损。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号